Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MC-1-50 · 3 trials · 6 indications
Dose-limiting toxicity after CD19 CAR-T cell infusion
| Arm | Type | Description |
|---|---|---|
| MC-1-50 | EXPERIMENTAL | Patients will be be treated with CD19 CAR- T cells |
| MC-1-50 cell preparation | EXPERIMENTAL | Patients will be be treated with CD19 CAR- T cells |
| Name | Type | Description |
|---|---|---|
| MC-1-50 | BIOLOGICAL | A single infusion of CD19 CAR-T cells will be administered intravenously after lymphodepletion chemotherapy |
Inclusion Criteria: 1. The patient or their guardian agrees to participate in this clinical trial and sign the ICF, indicating their understanding of the purpose and procedures of this clinical trial and willingness to participate in the study; 2. Age ≥ 18 years old , gender not limited; 3. Patient...
MC-1-50 is an investigational CD19-targeted CAR-T cell therapy being studied for B Cell Lymphoma, relapsed Acute Lymphoblastic Leukemia, and refractory Systemic Lupus Erythematosus (SLE). It is in Phase 1 clinical development and is not yet approved by regulatory authorities.
MC-1-50 targets CD19, a protein found on B cells. By directing CAR-T cells to CD19, the therapy is designed to eliminate malignant or autoreactive B cells involved in the diseases under study. This mechanism is being evaluated across oncology and autoimmune indications.
MC-1-50 is being developed by Precision BioSciences, Inc., a company publicly traded under the ticker DTIL. The therapy is currently in Phase 1 clinical trials, with studies conducted at sites in China.
MC-1-50 is in Phase 1 clinical development. All three of its listed trials are Phase 1 studies, and the drug remains investigational. It has not received FDA approval or any other regulatory approval for commercial use.
MC-1-50 is being studied in three Phase 1 trials: NCT06180174 for relapsed/refractory B Cell Lymphoma, NCT06641024 for relapsed/refractory B-ALL, and NCT06892145 for refractory SLE. The lymphoma and SLE trials are recruiting, while the B-ALL trial is not yet recruiting.
MC-1-50 is a CD19-targeted CAR-T cell therapy. Its clinical trials are titled as studies of CD19-targeted CAR-T cells, indicating that MC-1-50 is a form of this cell therapy approach. It is being evaluated in both blood cancers and autoimmune disease.